Compare HSBC Holdings plc (HSBC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Mesoblast Limited — how do they compare? HSBC Holdings plc trades at $104 (market cap $353.82B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: HSBC Holdings plc is far larger — about 160.1× Mesoblast Limited's market cap, and HSBC Holdings plc pays a 3.63% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| HSBC | MESO | |
|---|---|---|
Market Cap | $353.82B | $2.21B |
Sector | Technology | Technology |
52-Week High | $107.86 | $20.96 |
52-Week Low | $63.84 | $12.88 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.12, up 0.77% today, with a bullish technical signal from moving averages and support near $103. The bank reported strong Q2 2026 results with a 7% revenue increase and a $1 billion buyback, while net income margin improved to 34.54% in 2026. Analyst sentiment is mixed, with 38.1% buy ratings, but recent news includes a Citi downgrade citing a 40% stock run-up.
The outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and valuation concerns after the recent rally. Further upside depends on sustained revenue growth and effective capital allocation.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
